Myriad, Gene and UnitedHealthcare
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its engagement with UnitedHealthcare and its initial views on the potential financial ramifications to the company of this policy change.
On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...
TD Cowen analyst Daniel Brennan maintained a Hold rating on Myriad Genetics (MYGN – Research Report) today and set a price target of ...
Zacks.com on MSN8d
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?Myriad Genetics (MYGN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Myriad Genetics, Inc. (Symbol: MYGN) entered into oversold territory, hitting an RSI reading ...
SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and ...
Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback